Table 3 Therapeutics targeting the OCSCs
Agent | Target | Mechanism of action | Study phase |
|---|---|---|---|
DAPT | Notch pathway | GSIs | In vitro |
WFA | Notch pathway | Notch1 inhibitor | Both in vitro and in vivo |
Eugenol | Notch pathway | Notch-Hes1 inhibitor | Both in vitro and in vivo |
TF3 | Wnt/β-Catenin | β-Catenin down-regulator | In vitro |
Ginsenoside-Rb1 metabolite compound K | Wnt/β-Catenin | β-Catenin down-regulator | Both in vitro and in vivo |
Calcitriol | Wnt/β-Catenin | VDR down-regulator | Clinical trial phase 1 |
N-t-boc-Daidzein | PI3K/Akt/mTOR | Akt/mTOR down-regulator | In vitro |
DFOG | PI3K/Akt/mTOR | FOXM1 inhibitor | In vitro |
EriB | NF-κB | Nuclear p54 inhibitor | In vitro |
3PO | NF-κB | PFKFB3 inhibitor | In vitro |
PFK158 | NF-κB | PFKFB3 inhibitor | Clinical trial phase 1 |
VP | Hippo | YAP inhibitor | Both in vitro and in vivo |
dCD133KDEL | CD133 | CD133 monoclonal antibody | Both in vitro and in vivo |
ATRA | ALDH | ALDH1 inhibitor | Both in vitro and in vivo |
DDB2 | ALDH | ALDH1a1 inhibitor | Both in vitro and in vivo |
Metformin | multiple | CD44 down-regulator | Clinical trial phase 2 |
Salinomycin | multiple | Apoptotic proteins promoter | Both in vitro and in vivo |
CCBs | AKT/ERK pathway | Apoptotic proteins promoter | In vitro |